ABOS stock news · Acumen Pharmaceuticals
Get alerts for ABOS
Follow Acumen Pharmaceuticals (ABOS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABOSOn Friday evening, 12 health care stocks changed a lot in price, with Inovio up 292.6% and Precigen down 26.5%.
NeutralAcumen shares rose 10%, and the article says its Q3 report came out 4 days earlier. It gives no report details, so it does not change how we read Acumen's business.
On Friday, 12 health care stocks saw big price changes, with CareDx and Regeneron going up and Acumen dropping.
NeutralAcumen Pharmaceuticals shares fell, and the article says its Q3 report came out 4 days earlier. It gives no report figures, so the story does not show a change in the company's business outlook.
12 health care stocks are changing in price before the market opens, with NRX Pharmaceuticals going up and Acumen Pharmaceuticals dropping.
NeutralAcumen Pharmaceuticals shares fell about 78%, and the report says its Q3 results came out 4 days earlier. It gives no results or new company details, so this story does not change the business outlook.
Acumen Pharmaceuticals said its drug trial for sabirnetug did not succeed, so they will stop working on it.
Bad for ABOSAcumen's Alzheimer's drug did not improve patients' results versus placebo, and the company plans to stop developing it. This weakens Acumen's prospects, though it will review other options.
Acumen Pharmaceuticals, Inc. says it will hold an Investor Day on September 16, 2026.
NeutralAcumen will host an Investor Day and posted the slides; the filing gives no new clinical or financial results, so it does not change Acumen's outlook.
Acumen Pharmaceuticals, Inc. discloses operational outcomes and financial status (ABOS).
NeutralAcumen Pharmaceuticals has filed a Form 8-K detailing its results of operations and financial condition, which is crucial for investors to assess the company's current standing and future prospects. The immediate nature of this filing suggests that it could lead to significant market reactions based on the disclosed information.